Ondansetron

From WikiCover

Jump to: navigation, search

On June 26, 2007, KV Pharmaceutical announced that it has received approval from the U.S. Food and Drug Administration to market Ondansetron 4 mg. and 8 mg. Orally Disintegrating Tablets. These products will be marketed by the Company's wholly-owned subsidiary, ETHEX Corporation.

Ondansetron Orally Disintegrating Tablets (Zofran ODT, GlaxoSmithKline) are indicated for the prevention of postoperative nausea and vomiting, as well as nausea and vomiting associated with emetogenic cancer chemotherapy and radiotherapy. Zofran ODT had branded revenues of over $200 million as reported from May 2006 through May 2007.

Retrieved from "http://www.wikicover.com/Ondansetron"